In the life sciences sector, cross-border operational structures have evolved from a strategic choice to an industry standard. Whether it is an Israeli biotech establishing a U.S. subsidiary to access the talent pipelines of Stanford or MIT, a Chinese firm organizing its intellectual property (IP) in the U.S. to attract venture capital, or a European pharma company positioning itself closer to the FDA for clinical trials, establishing a U.S. presence is now a critical step for growth.
However, many companies underestimate the long-term accounting, tax, and compliance burdens that arise when these structures are poorly implemented. Success does not necessarily depend on the size of a company’s budget, but rather on whether they treat financial and tax infrastructure as a strategic priority from the day of incorporation.
Foreign life sciences firms pursue U.S. operations to gain access to specialized talent, leading academic medical centers, robust IP protections, and a deeper pool of investors. As the funding landscape becomes more competitive, institutional investors increasingly favor U.S.-based entities that own the IP and conduct R&D domestically. This preference mitigates the risks associated with geopolitical instability and currency volatility, while simplifying due diligence, enforcement, and exit planning.
While the cost of operating in the U.S.—particularly regarding payroll and laboratory space—often comes as a shock to foreign founders, the resulting market credibility and investor access typically justify the investment.
A critical early decision for these companies is determining where R&D activity “lives” legally and financially, a choice usually driven by IP ownership strategy. The most common model involves a foreign parent company funding a U.S. subsidiary. The subsidiary hires the research team and incurs the R&D expenses, subsequently invoicing the parent for reimbursement plus a markup. While this “cost-plus” arrangement is conceptually simple, two primary areas frequently create risk:
1. Documentation: Transfer pricing regulations require intercompany transactions to occur at “arm’s length,” mirroring terms that unrelated parties would agree upon. Tax authorities scrutinize these arrangements heavily. A formal intercompany agreement must define the markup percentage, billing cadence, and the scope of reimbursable costs. Crucially, this is not a “set it and forget it” document; it must evolve alongside the business. For instance, a company transitioning from a pure R&D cost center to a product distribution model must document this shift to avoid complications during IRS audits or M&A due diligence.
2. Intercompany Cash Flows: Operational failures often occur when parent companies are slow to settle cost-plus invoices, leaving the U.S. subsidiary struggling to meet payroll. Maintaining precise records of intercompany balances and establishing clear transfer mechanics is an operational necessity that is often overlooked until a crisis occurs.
One significant advantage of U.S.-based R&D is the Federal Research Tax Credit, which allows companies to offset current or future income taxes. Early-stage, pre-revenue companies in their first five years can even apply up to $500,000 annually to offset payroll taxes—a vital cash flow lifeline for firms awaiting clinical trial results.
However, the utility of these credits depends entirely on the quality of the supporting documentation. Because the IRS can examine records in the year the credits are claimed—not just the year they were generated—a company that earns a credit in Year 3 but doesn’t reach profitability until Year 15 must maintain records that can withstand scrutiny 12 years later. Standard five-to-seven-year retention policies are insufficient in these cases and can lead to significant losses of accumulated credits.
Beyond federal incentives, state-level programs can provide substantial support. For example, the Massachusetts Life Sciences Center offers tax credits to companies meeting specific hiring milestones. While location decisions involve many factors, the state-specific tax environment should be a primary consideration in early planning.
Cap table management is another frequent point of failure. Under IRS rules, an “ownership change” exceeding 50% over three years can trigger limitations on how previous losses and credits are utilized. Companies anticipating fundraising rounds, M&A, or an IPO must proactively track these changes. Additionally, the documentation for stock-based compensation used to attract top talent must be airtight.
The fundamental takeaway is that the ideal time to build a clean financial and tax infrastructure is before it becomes a necessity. While cross-border R&D structures are efficient and strategically sound, they require meticulous attention to detail. This diligence pays off during Series A or B funding rounds and M&A due diligence, where today’s investors and acquirers are more scrutinizing than ever. Discovering gaps in transfer pricing or R&D credit documentation during a deal is far more expensive than building the systems correctly from the start.
Photo: sesame, Getty Images
